Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
December 4, 2025 at 7:56 PM
Honored to deliver a keynote today at the 19th Scientific Day & 29th Annual Conference of Vall d’Hebron on collaborative, challenge-driven research with transformative health impact. #MYC #OMO-103 #Omomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
@vhio.bsky.social @icreacommunity.bsky.social #peptomyc
In parallel, I returned to @ucsfcancer.bsky.social, invited by @shulab2010.bsky.social, to give a talk on developing the first viable clinical #MYCinhibitor, #OMO-103, representing @vhio.bsky.social, @lsouceklab.bsky.social
and @icreacommunity.bsky.social.
and @icreacommunity.bsky.social.
January 18, 2026 at 10:32 AM
In parallel, I returned to @ucsfcancer.bsky.social, invited by @shulab2010.bsky.social, to give a talk on developing the first viable clinical #MYCinhibitor, #OMO-103, representing @vhio.bsky.social, @lsouceklab.bsky.social
and @icreacommunity.bsky.social.
and @icreacommunity.bsky.social.
🔴 OMO-103, a drug developed by @peptomyc, will be tested as a therapy for patients with advanced osteosarcoma.
The trial is funded by the @OSInstitute and aims to evaluate the clinical activity, safety and pharmacodynamics ➡️ https://linke.to/OSTEOMYCVHIO
#OSTEOMYC
The trial is funded by the @OSInstitute and aims to evaluate the clinical activity, safety and pharmacodynamics ➡️ https://linke.to/OSTEOMYCVHIO
#OSTEOMYC
January 16, 2025 at 7:02 AM
🔴 OMO-103, a drug developed by @peptomyc, will be tested as a therapy for patients with advanced osteosarcoma.
The trial is funded by the @OSInstitute and aims to evaluate the clinical activity, safety and pharmacodynamics ➡️ https://linke.to/OSTEOMYCVHIO
#OSTEOMYC
The trial is funded by the @OSInstitute and aims to evaluate the clinical activity, safety and pharmacodynamics ➡️ https://linke.to/OSTEOMYCVHIO
#OSTEOMYC
El fármaco OMO-103 se probará en ensayo como terapia en osteosarcoma avanzado www.diariomedico.com/medicina/onc...
El fármaco OMO-103 se probará en ensayo como terapia en osteosarcoma avanzado
Arranca un nuevo ensayo cuyo objetivo final sería aumentar las opciones terapéuticas y las tasas de supervivencia. Se prueba también en cáncer de páncreas metastásico.
www.diariomedico.com
January 18, 2025 at 6:25 PM
El fármaco OMO-103 se probará en ensayo como terapia en osteosarcoma avanzado www.diariomedico.com/medicina/onc...
In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.
December 3, 2025 at 6:56 AM
In triple-negative breast cancer (TNBC), #Omomyc/#OMO-103 shuts down DNA-repair gene programs, triggers DNA damage and — in combination with PARP inhibitors — restores response even in PARPi-resistant models.
“By conducting this study, we hope to gain valuable insights that will ultimately lead to improved outcomes for cancer patients.”
- Dr. Charles Lopez on a new clinical trial to evaluate OMO-103 in patients with a form of #PancreaticCancer: www.peptomyc.com/peptomyc-ann...
- Dr. Charles Lopez on a new clinical trial to evaluate OMO-103 in patients with a form of #PancreaticCancer: www.peptomyc.com/peptomyc-ann...
December 13, 2024 at 6:45 PM
“By conducting this study, we hope to gain valuable insights that will ultimately lead to improved outcomes for cancer patients.”
- Dr. Charles Lopez on a new clinical trial to evaluate OMO-103 in patients with a form of #PancreaticCancer: www.peptomyc.com/peptomyc-ann...
- Dr. Charles Lopez on a new clinical trial to evaluate OMO-103 in patients with a form of #PancreaticCancer: www.peptomyc.com/peptomyc-ann...
Peptomyc obtiene cinco millones de euros en ronda de financiación
Peptomyc obtiene cinco millones de euros en ronda de financiación
Peptomyc ha anunciado el cierre de una ronda de cinco millones de euros. El objetivo es avanzar en la siguiente etapa de desarrollo de OMO-103, el primer inhibidor directo de MYC con validación clínica. La operación la lideraron Alta Life Sciences y Aurora Science, con la participación de nuevos...
elreferente.es
April 9, 2026 at 11:11 AM
Peptomyc obtiene cinco millones de euros en ronda de financiación